10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Ana Antunes¹, Luis Alvarez-Vallina^{2

3}, Federico Bertoglio⁴, Nicolas Bouquin⁵, Stéphanie Cornen⁶, Francis Duffieux⁷, Pierre Ferré⁸, Raphaëlle Gillet⁵, Christian Jorgensen^{9

10}, Mark B Leick¹¹, Bernard Maillère¹², Hélène Negre¹³, Mireia Pelegrin¹⁴, Nicolas Poirier¹⁵, Dietmar Reusch¹⁶, Bruno Robert¹⁷, Guy Serre¹⁸, Alain Vicari¹⁹, Martin Villalba¹⁴, Christoph Volpers²⁰, Gavin Vuddamalay¹, Hervé Watier²¹, Thierry Wurch²², Lennart Zabeau²³, Stefan Zielonka²⁴, Baolin Zhang²⁵, Alain Beck²⁶, Pierre Martineau¹⁷

Affiliations

¹ MabDesign, Lyon, France.
² Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
³ H120-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain.
⁴ Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address.
⁵ REGIMBEAU, Paris - 69006 Lyon, France.
⁶ Innate Pharma, Marseille, France.
⁷ Large Molecules Research, Sanofi, Vitry-Sur-Seine, France.
⁸ Compugen Ltd, Holon, Israel.
⁹ IRMB, université de Montpellier, Inserm U1183, Montpellier, France.
¹⁰ Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, Montpellier, France.
¹¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
¹² Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
¹³ Institut de Recherches Internationales Servier, Suresnes, France.
¹⁴ IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France.
¹⁵ OSE Immunotherapeutics, Nantes, France.
¹⁶ Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany.
¹⁷ IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.
¹⁸ Institut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France.
¹⁹ Calypso Biotech SA, Plan-les-Ouates, Switzerland.
²⁰ Michalski Huettermann & Partner, Frankfurt/Main, Germany.
²¹ CEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France.
²² Evotec, Toulouse, France.
²³ Orionis Biosciences BV, Ghent, Belgium.
²⁴ Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
²⁵ Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
²⁶ Biologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France.

PMID: 37184206
PMCID: PMC10187075
DOI: 10.1080/19420862.2023.2211692

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Ana Antunes et al. MAbs. 2023 Jan-Dec.

. 2023 Jan-Dec;15(1):2211692.

doi: 10.1080/19420862.2023.2211692.

Authors

Affiliations

¹ MabDesign, Lyon, France.
² Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
³ H120-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain.
⁴ Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address.
⁵ REGIMBEAU, Paris - 69006 Lyon, France.
⁶ Innate Pharma, Marseille, France.
⁷ Large Molecules Research, Sanofi, Vitry-Sur-Seine, France.
⁸ Compugen Ltd, Holon, Israel.
⁹ IRMB, université de Montpellier, Inserm U1183, Montpellier, France.
¹⁰ Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, Montpellier, France.
¹¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
¹² Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
¹³ Institut de Recherches Internationales Servier, Suresnes, France.
¹⁴ IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France.
¹⁵ OSE Immunotherapeutics, Nantes, France.
¹⁶ Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany.
¹⁷ IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.
¹⁸ Institut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France.
¹⁹ Calypso Biotech SA, Plan-les-Ouates, Switzerland.
²⁰ Michalski Huettermann & Partner, Frankfurt/Main, Germany.
²¹ CEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France.
²² Evotec, Toulouse, France.
²³ Orionis Biosciences BV, Ghent, Belgium.
²⁴ Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
²⁵ Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
²⁶ Biologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France.

PMID: 37184206
PMCID: PMC10187075
DOI: 10.1080/19420862.2023.2211692

Abstract

The annual "Antibody Industrial Symposium", co-organized by LabEx MAbImprove and MabDesign, held its 10th anniversary edition in Montpellier, France, on June 28-29, 2022. The meeting focused on new results and concepts in antibody engineering (naked, mono- or multi-specific, conjugated to drugs or radioelements) and also on new cell-based therapies, such as chimeric antigenic receptor (CAR)-T cells. The symposium, which brought together scientists from academia and industry, also addressed issues concerning the production of these molecules and cells, and the necessary steps to ensure a strong intellectual property protection of these new molecules and approaches. These two days of exchanges allowed a rich discussion among the various actors in the field of therapeutic antibodies.

Keywords: Antibody engineering; Antibody industrial symposium; Intellectual property; antibody-related molecules; biotherapeutics; cell-based therapies; congress; research translation into clinic; therapeutic antibodies.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

References

1. Parthiban K, Perera RL, Sattar M, Huang Y, Mayle S, Masters E, Griffiths D, Surade S, Leah R, Dyson MR, et al. A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing. MAbs. 2019;11(5):884–12. PMID:31107136. doi:10.1080/19420862.2019.1618673. - DOI - PMC - PubMed
1. Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335. PMID:33103593. doi:10.1080/19420862.2020.1829335. - DOI - PMC - PubMed
1. Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494–508.e5. PMID:35452603. doi:10.1016/j.ccell.2022.04.001. - DOI - PMC - PubMed
1. Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848–59. PMID:36097221. doi:10.1038/s41591-022-01959-0. - DOI - PMC - PubMed
1. Jin H, D’Urso V, Neuteboom B, McKenna SD, Schweickhardt R, Gross AW, Fomekong Nanfack Y, Paoletti A, Carter C, Toleikis L, et al. Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. OncoImmunology. 2021;10(1):1958590. PMID:34484871. doi:10.1080/2162402X.2021.1958590. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Affiliations

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources